On November 2, 2026, South Africa's Aspen Pharmacare told the Johannesburg Stock Exchange it will sell the European commercialisation rights, registrations, marketing authorisations and related intellectual property for Ovestin, its estriol-based menopause treatment, to Ennogen Healthcare International for €197 million (about $220 million). Ennogen will also buy roughly €4 million of inventory, so the immediate deal value is about €201 million (Reuters via CNBC Africa; Business Insider Africa). Completion depends on Ennogen's financing arrangements becoming unconditional, according to Business Insider Africa.

Why It Matters

**Someone just paid about 15 times earnings for a decades-old vaginal-estrogen brand.** That's a useful price for anyone valuing the GSM market. Vaginal dryness and painful sex are among the most common and least treated menopause symptoms. The treatment options run from prescription local estrogens like Ovestin to the over-the-counter moisturisers, lubricants and "intimate care" brands investors are now funding (see [*Dry Spell Over*](/stories/gloriah-600k-seed-vaginal-dryness)). A specialty buyer paying this much for an off-patent product, and keeping the original maker as a 10-year supplier, suggests demand for local estrogen is stable and expected to grow. **The deal also comes as regulators reconsider menopause hormones.** In the US, the FDA has been removing boxed warnings from hormone therapy labels, and officials have floated over-the-counter access to vaginal estrogen (see [*Patchy Supply*](/stories/estradiol-patch-shortage-fda-action)). European demand is a separate market, but the trend is the same in both: local estrogen is moving from a reluctant prescription toward a mainstream sexual-health product. For DTC menopause platforms and intimate-wellness brands, the question is whether low-dose vaginal estrogen becomes something they can sell directly or something they compete against.

Aspen isn't fully exiting. Under long-term supply agreements it will keep manufacturing and supplying the active ingredient and the cream formulation of Ovestin in Europe for at least 10 years. It will also provide strategic support services for five years at €1 million a month, worth up to €60 million in total, and transitional services for up to three years while registrations and commercial operations move over. Business Insider Africa reports that a separate transitional distribution agreement pays Aspen 4% of Ovestin's net sales during the handover.

The figures show a small, profitable brand. Ovestin generated about R756 million (~$45 million) in revenue and R238 million in after-tax profit in Aspen's 2026 financial year. Aspen expects a R2 billion accounting gain on the sale. Billionaires.Africa calculates the price at about 15 times annual after-tax profit. By our arithmetic that is roughly 4–5 times revenue. Aspen describes the deal as part of a strategy to "unlock value" from assets outside its emerging-markets core, following a R27 billion Asia-Pacific sale this year, and says share buybacks remain its preferred use of surplus cash.

Ovestin is best known in Europe as a local estriol vaginal cream for menopausal vaginal dryness, irritation and discomfort, which doctors call vaginal atrophy or genitourinary syndrome of menopause (GSM). UK pharmacy listings describe it as working locally with low absorption into the bloodstream, unlike systemic HRT tablets or patches.

Sources

Update — 2026-11-03

Initial entry — story first created.